Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Wu HL, Webb GM, Fuchs SP, Pessoa CT, Hwang JM, Fisher HK, McCullen AJ, Humkey MC, Brown MK, Waytashek CM, Boyle CD, Kukula KA, Potter SK, Devlin G, Elmore ZC, Hull JA, Zikos J, Swanson T, Armantrout K, Chun K, Crank H, Bailey L, White R, Barber-Axthelm A, Fischer M, Smedley JV, Axthelm MK, Fennessey CM, Keele BF, Desrosiers RC, Magnani DM, Asokan A, Sacha JB. Adeno-associated virus gene therapy-mediated CCR5 blockade suppresses virus replication long term in SHIV-infected macaques. Sci Transl Med. 2026 Apr 29; 18(847):eadw1976.
-
Castelli JMP, Poljakov K, Jwa Y, Cunningham R, Cassidy ME, Gray MD, Sanchez Gaytan JN, Enstrom MR, Gastelum G, Wang Z, Linton JD, Rongvaux A, Taylor JJ, Adair JE. In vivo production of an anti-HIV antibody in mice by non-viral gene knockin in primate hematopoietic stem and progenitor cells. Mol Ther. 2026 May 06; 34(5):2754-2769.
-
D?az-Salinas MA, Benlarbi M, Chatterjee D, Nayrac M, Robidas M, Pinyakorn S, Phanuphak N, Sacdalan C, Medjahed H, Pr?vost J, Trautmann L, Pazgier M, Finzi A, Munro JB. Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity. J Virol. 2026 01 20; 100(1):e0166725.
-
Richard J, Grunst MW, Niu L, D?az-Salinas MA, Zhu L, Tolbert WD, Marchitto L, Zhou F, Bourassa C, Kim H, Boodapati SLT, Yang D, Chiu TJ, Chen HC, Benlarbi M, Beaudoin-Bussi?res G, Gottumukkala S, Li W, Dionne K, B?langer ?, Chatterjee D, Medjahed H, Hendrickson WA, Sodroski J, Lang ZC, Morton AJ, Huang RK, Matthies D, Smith AB, Kumar P, Mothes W, Munro JB, Pazgier M, Finzi A. The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC. Nat Commun. 2025 Dec 01; 16(1):10419.
-
Hahn PA, Shandilya S, da Costa LAB, da Silva LCF, O'Hagan D, Liang B, Engelman K, Gardner MR, Gao G, Fuchs SP, Martinez-Navio JM, Desrosiers RC, Ardeshir A, Magnani DM, Martins MA. The Immunogenicity of AAV-Encoded HIV-1 bNAbs in Rhesus Macaques Is Unaffected by a Short Course of the Immunomodulator CTLA4Ig. AIDS Res Hum Retroviruses. 2025 12; 41(12):567-579.
-
Ardeshir A, O'Hagan D, Mehta I, Shandilya S, Hopkins LLJ, Adamson L, Kuroda MJ, Hahn PA, da Costa LAB, Fuchs SP, Martinez-Navio JM, Gardner MR, Van Rompay KKA, Magnani DM, Lifson JD, Gao G, Farzan M, Desrosiers RC, Das J, Martins MA. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025 09; 645(8082):1020-1028.
-
Matsuda K, Harrison M, Wettstein E, Pederson J, Pullano AA, Bolkhovitinov L, Kim B, Steinberg I, Griesman T, Stuccio S, Rogan D, Patamawenu A, Shofner T, Wright NE, Webber JD, Van't Veer F, Roenicke R, Koory E, Roeder PM, Ober E, Leach B, Tsybovsky Y, Stephens T, Del Moral-Sanchez I, Bontjer I, McGinnes-Cullen LW, Chu E, Liang J, Torres JL, Lin RN, Tran AS, Dziubla G, Serebryannyy L, Narpala S, Lin B, Castro M, Ozorowski G, Ward AB, Sanders RW, Kwong PD, Guenaga J, Wyatt R, Morrison T, Connors M. Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response. Nat Commun. 2025 Jun 03; 16(1):5162.
-
Violari A, Otwombe K, Hahn W, Chen S, Josipovic D, Baba V, Angelidou A, Smolen KK, Levy O, Mkhize NN, Woodward Davis AS, Martin TM, Haynes BF, Williams WB, Sagawa ZK, Kublin JG, Polakowski L, Brewinski Isaacs M, Yen C, Tomaras G, Corey L, Janes H, Gray GE. Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newborns. J Clin Invest. 2025 Jun 02; 135(11).
-
Dankwa S, Kosman C, Dennis M, Giorgi EE, Vuong K, Pahountis I, Garza A, Binuya C, McCarthy J, Mayer BT, Ngo JT, Enemuo CA, Carnathan DG, Stanfield-Oakley S, Berendam SJ, Weinbaum C, Engelman K, Magnani DM, Chan C, Ferrari G, Silvestri G, Amara RR, Chahroudi A, Permar SR, Fouda GG, Goswami R. A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLoS One. 2024; 19(11):e0312411.
-
Zikos J, Webb GM, Wu HL, Reed JS, Watanabe J, Usachenko JL, Shaqra AM, Schiffer CA, Van Rompay KKA, Sacha JB, Magnani DM. FcRn-enhancing mutations lead to increased and prolonged levels of the HIV CCR5-blocking monoclonal antibody leronlimab in the fetuses and newborns of pregnant rhesus macaques. MAbs. 2024 Jan-Dec; 16(1):2406788.